Method for reducing T cell-mediated cytotoxicity in HIV using anti-idiotypic antibody
AssigneeSidney Kimmel Cancer Center
InventorsSybille Muller, Haitao Wang
Life of this patent
Estimating the term…
Abstract
The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.
Claims3
A method of reducing T cell-mediated cytotoxicity in HIV+ sera comprising administering a sufficient amount of an anti-idiotypic monoclonal antibody or binding fragment thereof having specific reactivity with an idiotope specifically bound by monoclonal antibody 1 F7 produced by hybridoma ATCC Accession No. HB 11286, and which idiotope is common to at least three types of human anti-HIV-1-antibody of differing specificites, but not significantly reactive with idiotypes of human non-HIV-1 antibodies.
Dependencies are inferred from the claim text.